Revenue
2016
2017
2018
2019
Enveric Biosciences, Inc. (ENVB)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $39.9M | $43.0M | $48.6M | $36.1M | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | $8.2M | $9.0M | $10.2M | $6.9M | — | — | — | — | — |
| Research & development | $2.8M | $2.8M | $7.3M | $8.0M | $4.8M | $174,083 | — | — | — | $55,104 | — | — | — | — | — |
| Operating expenses | $8.8M | $9.6M | $16.4M | $27.4M | $64.6M | $5.6M | $14.5M | $16.1M | $21.1M | $12.3M | — | — | — | — | — |
| Operating income | −$8.8M | −$9.6M | −$16.4M | −$27.4M | −$64.6M | −$5.6M | −$2.3M | −$7.1M | −$10.9M | −$5.4M | $32,811 | $27,211 | −$22,690 | −$31,395 | −$35,875 |
| EBITDAderived | −$8.6M | −$9.3M | −$16.1M | −$27.1M | −$64.0M | −$5.5M | −$31,237 | −$4.2M | −$7.7M | −$4.0M | — | — | — | — | — |
| Net income | −$8.8M | −$9.6M | −$17.3M | −$18.5M | −$49.0M | −$6.9M | −$2.4M | −$16.9M | −$9.1M | −$2.8M | −$33,644 | −$161 | −$24,621 | −$33,380 | −$39,441 |
| Basic EPSper diluted share | -$36.24 | -$228.48 | -$121.29 | -$13.00 | -$103.69 | -$1.19 | -$2.83 | -$20.47 | -$0.75 | -$0.21 | $0.00 | $0.00 | $0.00 | $0.00 | -$0.01 |
| Diluted EPSper diluted share | -$36.24 | -$228.48 | -$121.29 | -$13.00 | -$2.07 | -$1.19 | -$2.83 | -$20.47 | -$0.75 | -$0.21 | $0.00 | $0.00 | $0.00 | $0.00 | -$0.01 |